ES2804476T3 - Péptido antitumoral derivado de una región determinante de complementariedad de un anticuerpo monoclonal humanizado contra el transportador NaPI2B - Google Patents

Péptido antitumoral derivado de una región determinante de complementariedad de un anticuerpo monoclonal humanizado contra el transportador NaPI2B Download PDF

Info

Publication number
ES2804476T3
ES2804476T3 ES11849571T ES11849571T ES2804476T3 ES 2804476 T3 ES2804476 T3 ES 2804476T3 ES 11849571 T ES11849571 T ES 11849571T ES 11849571 T ES11849571 T ES 11849571T ES 2804476 T3 ES2804476 T3 ES 2804476T3
Authority
ES
Spain
Prior art keywords
cancer
peptide
cells
peptides
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11849571T
Other languages
English (en)
Spanish (es)
Inventor
Luiz Travassos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recepta Biopharma SA
Original Assignee
Recepta Biopharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recepta Biopharma SA filed Critical Recepta Biopharma SA
Application granted granted Critical
Publication of ES2804476T3 publication Critical patent/ES2804476T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/10—Bryophyta (mosses)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES11849571T 2010-12-14 2011-12-14 Péptido antitumoral derivado de una región determinante de complementariedad de un anticuerpo monoclonal humanizado contra el transportador NaPI2B Active ES2804476T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42285610P 2010-12-14 2010-12-14
PCT/IB2011/003053 WO2012080822A2 (en) 2010-12-14 2011-12-14 Antitumor peptide derived from a complementarity determining region of a humanized monoclonal antibody to napi2b transporter

Publications (1)

Publication Number Publication Date
ES2804476T3 true ES2804476T3 (es) 2021-02-08

Family

ID=46245158

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11849571T Active ES2804476T3 (es) 2010-12-14 2011-12-14 Péptido antitumoral derivado de una región determinante de complementariedad de un anticuerpo monoclonal humanizado contra el transportador NaPI2B

Country Status (8)

Country Link
US (2) US9193797B2 (https=)
EP (1) EP2654769B1 (https=)
JP (1) JP6087289B2 (https=)
BR (1) BR112013015001B1 (https=)
CO (1) CO6721014A2 (https=)
ES (1) ES2804476T3 (https=)
PT (1) PT2654769T (https=)
WO (1) WO2012080822A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016013258A2 (pt) * 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
CN105491524B (zh) * 2015-12-11 2019-04-26 小米科技有限责任公司 一种确定目标便携设备位置的方法和装置
JP7194180B2 (ja) * 2017-07-01 2022-12-21 レセプタ バイオファーマ エッシ ア ペプチドを使用する方法及び樹状細胞を調節する方法
EP3685166A2 (en) * 2017-09-20 2020-07-29 Mersana Therapeutics, Inc. Compositions and methods for predicting response to napi2b-targeted therapy
WO2022032228A1 (en) 2020-08-07 2022-02-10 The Broad Institute, Inc. Therapeutic targeting of phosphate dysregulation in cancer via the xpr1:kidins220 protein complex
KR102822203B1 (ko) 2020-12-29 2025-06-18 삼성전자주식회사 전력 공급 장치를 이용하여 오디오 출력 장치를 찾는 방법 및 그 전력 공급 장치
CN116514926B (zh) * 2023-06-25 2023-08-29 烟台药物研究所 一种抗肿瘤阳离子两亲肽及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9108652D0 (en) * 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
AU684348B2 (en) * 1994-06-07 1997-12-11 Nihon Medi-Physics Co., Ltd. Tumor affinity peptide, and radioactive diagnostic agent and adioactive therapeutic agent containing the peptide
US6689753B1 (en) 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
WO2005040219A1 (en) * 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
WO2009097128A1 (en) 2008-01-29 2009-08-06 Ludwig Institute For Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

Also Published As

Publication number Publication date
WO2012080822A9 (en) 2016-08-11
JP6087289B2 (ja) 2017-03-01
BR112013015001A8 (pt) 2018-04-17
CO6721014A2 (es) 2013-07-31
EP2654769A4 (en) 2017-10-25
EP2654769B1 (en) 2020-04-15
US20130315902A1 (en) 2013-11-28
US9193797B2 (en) 2015-11-24
US20160108132A1 (en) 2016-04-21
BR112013015001B1 (pt) 2021-10-13
US9896512B2 (en) 2018-02-20
PT2654769T (pt) 2020-07-16
BR112013015001A2 (pt) 2017-12-19
EP2654769A2 (en) 2013-10-30
JP2014510699A (ja) 2014-05-01
WO2012080822A2 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
US9896512B2 (en) Antitumor peptide derived from a complementarity determining region of a humanized monoclonal antibody to NAP12B transporter
EP3210625B1 (en) Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica)
ES2994374T3 (en) Antibody molecule-drug conjugates and uses thereof
ES2747273T3 (es) Anticuerpos anti-EpCAM y métodos de uso
US9198949B2 (en) Method and pharmaceutical composition for use in the treatment of cancer
KR20230145162A (ko) 표적 전달 이용을 위한 2가 섬유모세포 활성화 단백질 리간드
AU2014228777B2 (en) BH4 stabilized peptides and uses thereof
US10632179B2 (en) Methods and compositions for treating cancer
Kamysz et al. Antitumor activity of opiorphin, sialorphin and their conjugates with a peptide klaklakklaklak
US20220213187A1 (en) Compositions and methods related to xct antibodies
AU2016258123A1 (en) Radiotherapeutic and companion imaging agents to target MC1R
WO2025162471A1 (en) Antibodies and antibody-drug conjugates targeting ox40 and uses thereof
Tripodi Development of a novel class of cyclic NGR peptides for targeted drug delivery
US12344643B2 (en) Compositions and methods for inhibition of FOXP3
TW202604936A (zh) 一種多肽藥物偶聯物及其製備方法和應用
WO2026026981A1 (zh) 一种双特异性抗体、抗体偶联药物及其制备方法与应用
HK1199835B (en) Therapeutic peptides
Burns Specific Delivery of Therapeutics to Cancer Cells Using pHLIP